Yoko Harima MD, PhD, Presenter: Nothing to Disclose

Koshi Ikeda MD, PhD, Abstract Co-Author: Nothing to Disclose

Keita Utsunomiya MD, PhD, Abstract Co-Author: Nothing to Disclose

Atsushi Komemushi MD, PhD, Abstract Co-Author: Nothing to Disclose

Toshiko Shiga, Abstract Co-Author: Nothing to Disclose

Noboru Tanigawa MD, Abstract Co-Author: Nothing to Disclose

To assess the usefulness of pretreatment serum Apolipoprotein C-II (ApoC-II) measured with an Elisa-Kit that we produced and Matrix metalloproteinase-1(MMP-1) levels in predicting outcomes of chemoradiotherapy in patients with locally advanced cervical cancer (CC).

The study included a total of 87 patients with CC who underwent definitive chemoradiotherapy between February 2006 and May 2012 in our hospital. All patients after informed consent form approved by our University Review Board describing the experimental nature of the treatment. Age, tumor size, and pretreatment serum values of squamous cell carcinoma antigen (SCC), ApoC-II, MMP-1, Matrix metalloproteinase-2 (MMP-2), and a composite variable of ApoC-II divided by MMP-1 (ApoC-II/MMP-1) were analyzed. The endpoint was the correlations between the patient characteristics and overall, local relapse-free, and disease-free survival rate as estimated by univariate and multivariate Cox proportional-hazard model analysis and Kaplan-Meier method.

On univariate analysis with Cox proportional-hazard model, tumor size (p=0.002, p<0.001, p<0.001), MMP-1 (p=0.017, p=0.007, p=0.03), and ApoC-II/MMP-1 (p=0.001, p=0.014, p=0.005) were significant independent variables to predict overall, relapse-free, and disease-free survival rate. On multivariate analysis, ApoC-II/MMP-1was a significant independent predictor of overall survival rate (p=0.017), and tumor size was a significant independent predictor of local relapse-free (p=0.002) and disease-free survival rate (p=0.001). Using Kaplan-Meier method and the log-rank test, tumor size (p=0.001, p<0.001, p<0.001), ApoC-II (p< 0.001, p<0.001, p=0. 002), MMP-1 (p=0.009, p=0.011, p=0.032), and ApoC-II/MMP-1 (p=0.001, p=0.003, p=0.003) were significant predictors of overall, relapse-free, and disease-free survival rate.

The results of our study suggest that ApoC-II/MMP-1is the most important serum biomarker of outcomes of patients with CC after chemoradiotherapy.

ApoC-II/MMP-1 can be used as prognostic biomarker to improve clinical strategies for treatment of advanced cervical cancer after chemoradiotherapy.

Harima, Y, Ikeda, K, Utsunomiya, K, Komemushi, A, Shiga, T, Tanigawa, N, Serum Apolipoprotein C-II/Matrix Metalloproteinase-1 Level as Predictive Biomarker of Outcomes in Patients with Locally Advanced Cervical Cancer after Chemoradiotherapy.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14005535.html